<DOC>
	<DOCNO>NCT02737930</DOCNO>
	<brief_summary>The purpose study determine whether fluoxetine , selective serotonin reuptake inhibitor commonly use depression , enhance visual recovery acute ischemic stroke .</brief_summary>
	<brief_title>Fluoxetine Visual Recovery After Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>MRIconfirmed acute ischemic stroke result isolated homonymous visual field loss . Known hypersensitivity fluoxetine selective serotonin reuptake inhibitor National Institutes Health Stroke Scale score great 5 Premorbid modify Rankin Scale score great 2 Premorbid monocular binocular visual field deficit Premorbid retinopathy optic neuropathy Premorbid depression History cognitive impairment , dementia , neurodegenerative disorder History seizure disorder History mania hypomania History hyponatremia History angleclosure glaucoma elevate intraocular pressure Current alcohol abuse impair liver function Current use antidepressant medication Current use medication likely adverse interaction fluoxetine Current use medication likely impair poststroke recovery Contraindication MRI Pregnancy lactation Hemorrhagic transformation index stroke , result mass effect Enrollment another clinical trial time index stroke</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute ischemic stroke</keyword>
	<keyword>Homonymous hemianopia</keyword>
	<keyword>Homonymous quadrantanopia</keyword>
	<keyword>Visual field loss</keyword>
	<keyword>Post-stroke recovery</keyword>
	<keyword>Fluoxetine</keyword>
	<keyword>Selective serotonin reuptake inhibitor</keyword>
</DOC>